NGS Streamlines Biomarker Testing in Solid Tumors
According to Chen, PharmD, MS, BCOP, CPP, next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors.
- Experts such as Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, discuss the benefits of NGS.
- Other notable specialists, including Mark Agulnik, MD, and Mrinal M. Zuckerman, MD, also share their insights.
NGS streamlines biomarker testing, enabling more effective treatment planning for patients with solid tumors.
Additional experts, such as Naval G. Daver, MD, and Jessica Altman, MD, contribute to the discussion on the role of NGS in oncology.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- University of Central Arkansas establishes NWA advisory council - Talk Business & Politics
- Be ready for pea-sized hail with thunderstorms in Central West Florida Monday – gusts may reach 40 mph
- New corporate espionage claims emerge, centered on two highly valued 401(k) admin startups | TechCrunch
- After Service Dog Helped Her Recovery Journey, Grad Student Is Spreading the Word About Their Important Role
- OpenAI says over a million people talk to ChatGPT about suicide weekly | TechCrunch
- Sweden’s still ahead in the preparedness game — and now it means business
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Edwards shares superior long-term outcomes from TAVR studies
- Robotaxi companies must do more to prove safety, Waymo co-CEO says | TechCrunch
- Fang-tastic night for Trunk or Treating